<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03091998</url>
  </required_header>
  <id_info>
    <org_study_id>IRB # 16-004850</org_study_id>
    <nct_id>NCT03091998</nct_id>
  </id_info>
  <brief_title>Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support</brief_title>
  <acronym>CD-NP/LVAD</acronym>
  <official_title>A Phase I Trial to Determine Safety and Efficacy of Chronic Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The worldwide use of left ventricular assist devices (LVAD), which is mechanical device to&#xD;
      improve hemodynamic function, has improved the outcomes of severe heart failure (HF) patients&#xD;
      leading to the continued annual increase in the number of LVAD implantations. However LVAD&#xD;
      support still results in major complications such as renal failure or gastrointestinal&#xD;
      bleeding. The investigators hypothesize that such major complications may be due to&#xD;
      endothelial dysfunction induced by the lack of pulsatility, which may be improved by an&#xD;
      innovative designer natriuretic peptide, CD-NP. They have demonstrated its favorable actions&#xD;
      in animal models as well as humans, and tested its safety in LVAD patients. They hypothesize&#xD;
      that CD-NP will have renal and endothelial protective actions through its receptor GC-A and&#xD;
      GC-B. Thus, the investigators will test their hypothesis with a highly translational approach&#xD;
      to examine CD-NP's role in endothelial and renal protection.&#xD;
&#xD;
      The aim is to determine safety and tolerability together with cGMP activating, neurohumoral&#xD;
      modulating and renovascular protective properties of chronic subcutaneous delivery of CD-NP&#xD;
      compared to placebo in stable LVAD patients for 3 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stable patients with LVAD implantation (3 months s/p implantation) will undergo 3-day testing&#xD;
      in the Mayo Clinic's Clinical Research and Trials Unit. They will undergo daily subcutaneous&#xD;
      injection of CD-NP, or placebo, for 3 days with hemodynamic monitoring, ECHO, endothelial&#xD;
      function assessment, and renal blood flow monitoring. Blood and urine samples will also be&#xD;
      collected and assayed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No funding available&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 30, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Injection of CD-NP vs Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The Research Pharmacists will manage the randomization of the study and release information at the conclusion, once all participants have been recruited and completed study measures.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hypotension</measure>
    <time_frame>2 weeks</time_frame>
    <description>To assess safety and tolerability (without symptomatic hypotension or mean blood pressure &lt;70 mmHg) of chronic continuous subcutaneous infusion administration of CD-NP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Outcome Characterization</measure>
    <time_frame>2 weeks</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) assessed by plasma CD-NP and cGMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function</measure>
    <time_frame>2 weeks</time_frame>
    <description>Estimated GFR from creatinine clearance and</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>2 weeks</time_frame>
    <description>Measurement by Reactive Hyperemia-peripheral arterial tonometry (RHI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure</condition>
  <condition>Left Ventricular Assist Device</condition>
  <condition>Natriuretic Peptide</condition>
  <arm_group>
    <arm_group_label>Study Drug (CD-NP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a single subcutaneous injection of CD-NP (5 ug/kg) for 3 days running</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single subcutaneous injection (~1 mL) of normal saline for 3 days running</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD-NP</intervention_name>
    <description>Participants will receive a subcutaneous injection of CD-NP (5 mcg / kg) daily for 3 days</description>
    <arm_group_label>Study Drug (CD-NP)</arm_group_label>
    <other_name>Cenderitide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive an ~ 1mL subcutaneous injection of normal saline, in lieu of Study Drug, for 3 days</description>
    <arm_group_label>Placebo (saline)</arm_group_label>
    <other_name>0.9% normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and non-pregnant/post-menopausal/sterile females, ages 18-90, in end-stage HF&#xD;
             with LVAD support who are stable in the healed stage at least 3 months from the LVAD&#xD;
             implant (Destination therapy only) (the post-menopausal state is defined as the&#xD;
             absence of menses for ≥ 1 year or serum follicle-stimulating hormone ≥ 20 IU/L;&#xD;
             sterilization in the female is defined as bilateral tubal occlusion for ≥ 6 months,&#xD;
             bilateral oophorectomy, or complete hysterectomy)&#xD;
&#xD;
          -  Be willing to provide informed consent.&#xD;
&#xD;
          -  All cardiac medications must be at stable doses 4 weeks prior to enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy or other adverse reactions to exogenous natriuretic peptides (CD-NP or&#xD;
             its components, nesiritide, other natriuretic peptides, or related compounds).&#xD;
&#xD;
          -  Women who are pregnant, or breast-feeding.&#xD;
&#xD;
          -  Having received nesiritide within 7 days prior to entry into the study.&#xD;
&#xD;
          -  Having received any investigational drug or device within 30 days prior to entry into&#xD;
             the study.&#xD;
&#xD;
          -  Clinically unstable patients (e.g. mean blood pressure &lt; 70 mmHg, ongoing requirement&#xD;
             for vasopressors, or mechanical ventilation).&#xD;
&#xD;
          -  Recent hospitalization for decompensated HF or recent defibrillation for cardiac&#xD;
             resuscitation within 30 days prior to randomization.&#xD;
&#xD;
          -  Patients with guarded prognosis who are unlikely to derive meaningful benefit from&#xD;
             CD-NP.&#xD;
&#xD;
          -  Presence of cardiac lesions or comorbidities that may contraindicate the use of&#xD;
             natriuretic peptides, such as clinically significant cardiac valvular stenosis,&#xD;
             hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis,&#xD;
             primary pulmonary hypertension, or uncorrected congenital heart disease that&#xD;
             contraindicates the use of vasodilators.&#xD;
&#xD;
          -  Symptomatic carotid artery disease, known critical carotid stenosis, or stroke within&#xD;
             the past 3 months&#xD;
&#xD;
          -  Requirement of pressors for maintenance of blood pressure.&#xD;
&#xD;
          -  Intra-aortic blood pump use.&#xD;
&#xD;
          -  Severe aortic or mitral stenosis or significant LV outflow tract obstruction.&#xD;
&#xD;
          -  Clinically significant renal artery stenosis &gt; 50%&#xD;
&#xD;
          -  Baseline hemoglobin &lt; 9.0 g/dl.&#xD;
&#xD;
          -  Serum sodium &lt; 130 mEq/L, potassium &lt; 3.6 mEq/L, or magnesium &lt; 1.5 mEq/L.&#xD;
&#xD;
          -  Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) at least 5&#xD;
             times the upper limit of normal or bilirubin at least 5 times the upper limit of&#xD;
             normal&#xD;
&#xD;
          -  Creatinine clearance (CrCl) &lt; 30 ml.min-1.1.73m-2, as calculated by Cockcroft-Gault&#xD;
             formula(67) and adjusted for body surface area within 3 months or requirement for&#xD;
             dialysis.&#xD;
&#xD;
          -  Written history of alcohol or drug abuse within the past 6 months.&#xD;
&#xD;
          -  Inability to communicate effectively with study personnel.&#xD;
&#xD;
          -  BMI &gt;40&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomoko Ichiki, M.D.Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Tomoko Ichiki, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

